Michael Zinda - 04 Mar 2025 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Mar 2025, 17:00:09 UTC
Prior SEC filing
01 Apr 2024
Next SEC filing
14 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Steve Forte, Attorney-in-Fact

Key filing fact

Michael Zinda filed Form 4 for Repare Therapeutics Inc. (RPTX) on 06 Mar 2025.

Key facts

  • This page summarizes Michael Zinda's Form 4 filing for Repare Therapeutics Inc. (RPTX).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 06 Mar 2025, 17:00.

Change

  • Previous filing in this sequence was filed on 01 Apr 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPTX transaction

Common Shares

Award

Transaction value
$0
Shares
+14,000
Change %
+19%
Price
$0.000000
Shares after
85,908
Date
04 Mar 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RPTX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
$0
Shares
+75,000
Change %
Price
$0.000000
Shares after
75,000
Date
04 Mar 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
75,000
Exercise price
$1.17
Footnotes
F2
RPTX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
$0
Shares
+85,000
Change %
Price
$0.000000
Shares after
85,000
Date
04 Mar 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
85,000
Exercise price
$1.17
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date.

Footnote F2

The option will vest in in full on March 4, 2026, subject to Reporting Person continuing to provide service through such date.

Footnote F3

Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .